Clinical Network Services (UK) Ltd
Clinical Network Services (CNS) is an Australian, New Zealand and UK based service group, offering full and integrated drug development consultancy to small – medium sized Biotech companies from inception through to end of phase II clinical trial programs. CNS offers a unique service that brings together BioDesk; an intelligent product development and regulatory planning service, with our highly experienced regional clinical operations and data management teams.
BioDesk is a team of in-house scientists and commercial drug development experts, who work closely with our clients from the earliest of planning stages. Together they create and manage Drug Development Plans, including all stages of pre-clinical/CMC programs that embrace global regulatory strategies whilst leveraging our unique regional advantage.
Australia and New Zealand have an outstanding product development timeline advantage due to our access to a pragmatic regulatory environment that makes it possible to add value to the global regulatory dossier and enter the clinic quickly, without the need for prior approval from another regulatory agency. Our clients have often established initial proof-of-concept quickly, and have enjoyed a time(cost) saving when compared to the more resource-intensive strategy of applying for an IND or CTA.
CNS has worked with clients whose cumulative acquisition price exceeds US$16.5billion; many of these clients initially fast-tracked their programs by running their phase 1 & 2 studies in Australia and New Zealand.
Further information on CNS can be found at www.clinical.net.au
Critical Pharmaceuticals is a privately funded clinical stage biotechnology company focused on developing improved versions of marketed biologic drugs using it’s patented drug delivery platform technologies.
The company’s lead products are an intranasal human growth hormone product, targeted at a $3.1bn market, and CP046 intranasal teriparatide product for the treatment of osteoporosis, a $1.2bn market. The development pathway for both programs is clear and low risk as it involves drugs with well established efficacy and toxicity, and previous exposure to man in a successful Phase I clinical trials.
Critical Pharmaceuticals patented CriticalMix™ and CriticalSorb™ technology platforms are applicable to the large and fast growing market of biological drugs. The technology has been validated in collaboration with other biopharmaceutical companies with two partner programs poised to enter clinical development.
The products and platform technology has extensive IP protection, including granted US patents.
Dr Gareth KingCEO
Datatrial is a clinical technology organisation with supporting biometrics services. Our innovative nowEDC™ solution provides data capture, verification and validation, query management, data extract, randomization and real-time reporting in one integrated system. nowEDC is easy-to-use and is highly configurable, making it a natural fit for complex workflows and trial designs.
Based on the ground breaking Nature publication ‘Automated design of ligands to polypharmacological profiles’ and with several commercial collaborations underway ex scientia is the first company to develop a systematic approach to tailoring drugs against polypharmacology profiles for superior clinical efficacy. We are exploiting our advanced technologies to develop compounds with tailored selectivity and in particular a portfolio of efficacious bispecific drugs.
Our bispecific design technology delivers efficacious small molecule drugs binding novel target combinations, either within or between gene families. By hitting multiple nodes in the cellular network simultaneously better clinical efficacy can be achieved.
Non-specific, promiscuous interactions with undesired proteins frequently cause drug toxicity and adverse effects. Our tailored selectivity technology can be applied to the discovery of drug candidates with desired selectivity, thereby reducing side effects and toxicity.
Advances in phenotypic screening are opening new ways to deliver improved medicines. Our phenotypic design technologies can generate and optimise effective molecules using high content phenotypic data without prior consideration of the targets.
Professor Andrew HopkinsCEO
Dr Mark SwindellsChief Operating Officer
Dr Denise BarraultChief Commercial Officer
Fusion Antibodies is a CRO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.
Meet with potential companies looking to access our royalty free, fee-for-service antibody engineering expertise in:
Transient & Stable cell line development
We are also seeking partnerships with companies interested in the area of EGFR pathway to develop our in-house double targeting humanized therapeutic Antibody Fsn1006.
Glythera Limited is a biotechnology company specializing in the development of platform technologies for next generation biotherapeutics. We have 2 core programmes:
- PermaLink™ - a novel, stable, highly cysteine-specific conjugation platform for antibody drug conjugates (ADCs)
PermaLink™ is associated with enhanced anti-tumour activity in vivo vs maleimide in comparative ADC models. It is suitable for cleavable and non-cleavable systems
- PermaCarb™ - a novel sialylation correction platform which can (i) improve bioavailability & enhance product performance and (ii) remove the issue of sialic acid contamination. It is particularly appropriate for the development of biobetters and biosimilars
PermaCarb™ has been validated vs several biotherapeutics, including FSH and etanercept
Based in the NE of England, Glythera has dedicated bioprocessing and chemistry laboratories enabling us to conduct in-house evaluations for our partners to progress applications of PermaLink™ and PermaCarb™ technologies.
We are seeking license collaborations for PermaLink™ and out-license partners for PermaCarb™
Illetrop commercialises products and services in diverse fields including in oncology, inflammatory diseases, primary cells and antibodies.
Mr Douglas ThomsonDirector
KWS BioTest Ltd.
KWS BioTest is an established contract research organization providing a wide range of drug discovery services spanning preclinical development from early cell biology, through efficacy models to clinical sample analysis.
KWS BioTest provides clients with a powerful combination of world-leading scientific expertise coupled with the latest methods and technologies to ensure the highest levels of quality and service at all times. We specialise in the areas of immunology, inflammation and infection and work closely with our clients in the testing of their novel small molecules, biologics and ADCs as treatments for human disease, including specific experience across global vaccine development initiatives. We can generate data to support all stages of compound and molecule development to maximise the chance of successful progression to each important project milestone.
Our dedicated solutions for our clients often feature bespoke study designs, allowing them to benefit from our extensive experience across both therapeutic areas and molecule classes. Our team of expert scientists can provide support for both individual studies and as part of larger projects as a virtual extension of our clients’ laboratory capabilities. We can assist in the interpretation of complex programs of work in target validation, lead optimisation, candidate selection, discovery support and clinical sample analysis, increasing the chance of molecules succeeding and helping bring them to the clinic faster.